Connection

Maria De Santis to Carcinoma, Renal Cell

Back to Details
This is a "connection" page, showing publications Maria De Santis has written about Carcinoma, Renal Cell.
Maria De Santis
Connection Strength
0.115
Carcinoma, Renal Cell
  1. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). Eur J Cancer. 2019 01; 107:37-45.
    View in: PubMed
    Score: 0.115
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.